Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma

INTRODUCTION: Dupilumab, a fully human anti-IL-4Rα monoclonal antibody, inhibits signaling of both interleukin (IL)-4 and IL-13, which are key drivers of type 2-mediated inflammation. Dupilumab is approved in the EU, USA, and other countries for the treatment of adults with inadequately controlled m...

Descripción completa

Detalles Bibliográficos
Autores principales: Busse, William W., Maspero, Jorge F., Rabe, Klaus F., Papi, Alberto, Wenzel, Sally E., Ford, Linda B., Pavord, Ian D., Zhang, Bingzhi, Staudinger, Heribert, Pirozzi, Gianluca, Amin, Nikhil, Akinlade, Bolanle, Eckert, Laurent, Chao, Jingdong, Graham, Neil M. H., Teper, Ariel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960488/
https://www.ncbi.nlm.nih.gov/pubmed/29725983
http://dx.doi.org/10.1007/s12325-018-0702-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960488/
https://www.ncbi.nlm.nih.gov/pubmed/29725983
http://dx.doi.org/10.1007/s12325-018-0702-4

Ejemplares similares